Xeltis recently announced that the FDA has granted Breakthrough Device designation for the company’s aXess vascular acce ...

Simcere Pharmaceuticals Group Ltd. recently announced that findings from the TASTE-2 clinical study have shown that the admini ...

Healionics Corporation announced that its Stargraft arteriovenous (AV) graft for dialysis access has been granted ...

Arsenal Medical announced the initiation of the EMBO-02 clinical study of its NeoCast liquid embolic to treat chronic ...

CVRx, Inc. announced recently that the Centers for Medicare and Medicaid Services (CMS) assigned the company’s Barostim p ...

November 11, 2024—iVascular announced the initiation of OPAL, a first-in-human study of Amber, the company’s embolic liquid ...

Humacyte, Inc. recently announced the presentation of results from the V007 phase 3 clinical trial of the company’s acel ...

R3 Vascular Inc. recently announced that the FDA granted investigational device exemption (IDE) approval to initiate the compa ...

Akura Medical, a Shifamed portfolio company focused on venous thromboembolism care, announced recently that the FDA has approve ...

Dr. Silver moderates a panel of experts who discuss their experiences with the Neuroguard IEP® System, insights into the data, device design characteristics, and impact on the field.

Front Line Medical Technologies Inc. COBRA-OS REBOA (large vessel balloon occlusion device; 4-F; 25-mm-diameter balloon; guidewire-free) Aortic Temporary occlusion of large blood vessels and/or ...

Endovascular Today (ISSN 1551-1944 print and ISSN 2689-792X online) is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the ...